Technology
Products
Market
About us
News
- Regulatory news
Investor relations

Live Webcast

of the announcement of RP101 Phase II clinical results

2020-03-12

Redwood Pharma

We develop ophthalmic drugs that address major medical needs. We focus on early-stage clinical development. Our long-term strategy is to enter into licence agreements with other drug companies who will in turn introduce products for the global market.

Welcome
Technology
Products
Market
About us
News
- Regulatory news
Investor relations
- Reports
- Presentations
Privacy Policy

Kontakt

Martin Vidaeus – VD
070-232 29 29
martin.vidaeus@redwoodpharma.com

Östermalmstorg 1
114 42 Stockholm, Sverige